Noted biotech investment firm OrbiMed slid from first place to 14th in STAT’s latest annual ranking of venture capital firm performance.
OrbiMed, which is based in New York City, is one of the most prominent players in the health care investing world. It manages $18 billion in assets, some of which the firm has invested in startups like Acceleron Pharma, which was acquired by Merck last year for $11.5 billion.
But OrbiMed’s performance faltered at a time when several other VCs were seeing success, according to performance figures STAT obtained through records requests. The top three firms in 2022’s ranking were Alta Partners, ARCH Venture Partners, and Flagship Pioneering, which each rose multiple spots in STAT’s list.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
